Curcumin Lowers Serum Lipids and Uric Acid in Subjects with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, L.E. Simental-Mendiá, Amirhossein Sahebkar

    Research output: Contribution to journalArticle

    122 Citations (Scopus)


    © 2016 Wolters Kluwer Health, Inc.Nonalcoholic fatty liver disease (NAFLD) is one of the most common hepatic diseases in the general adult population. Dyslipidemia, hyperuricemia, and insulin resistance are common risk factors and accompanying features of NAFLD. Curcumin is a dietary natural product with beneficial metabolic effects relevant to the treatment of NAFLD. Aim: To assess the effects of curcumin on metabolic profile in subjects with NAFLD. Methods: Patients diagnosed with NAFLD (grades 1-3; according to liver sonography) were randomly assigned to curcumin (1000 mg/d in 2 divided doses) (n = 50) or control (n = 52) group for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, lipid profile, glucose, insulin, glycated hemoglobin, and uric acid concentrations were measured at baseline and after 8 weeks of follow-up. Results: Eighty-seven subjects (n = 44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P
    Original languageEnglish
    Pages (from-to)223-229
    JournalJournal of Cardiovascular Pharmacology
    Issue number3
    Publication statusPublished - 2016


    Cite this